These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9470808)

  • 1. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
    Sahmoud T; Postmus PE; van Pottelsberghe C; Mattson K; Tammilehto L; Splinter TA; Planting AS; Sutedja T; van Pawel J; van Zandwijk N; Baas P; Roozendaal KJ; Schrijver M; Kirkpatrick A; Van Glabbeke M; Ardizzoni A; Giaccone G
    Eur J Cancer; 1997 Nov; 33(13):2211-5. PubMed ID: 9470808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
    Planting AS; van der Burg ME; Goey SH; Schellens JH; van den Bent MJ; de Boer-Dennert M; Stoter G; Verweij J
    Ann Oncol; 1995 Jul; 6(6):613-5. PubMed ID: 8573543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
    van Meerbeeck J; Debruyne C; van Zandwijk N; Postmus PE; Pennucci MC; van Breukelen F; Galdermans D; Groen H; Pinson P; van Glabbeke M; van Marck E; Giaccone G
    Br J Cancer; 1996 Sep; 74(6):961-3. PubMed ID: 8826866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
    Kindler HL; Herndon JE; Zhang C; Green MR;
    Lung Cancer; 2005 Jun; 48(3):423-8. PubMed ID: 15893012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pleural mesothelioma: a phase II trial with docetaxel.
    Vorobiof DA; Rapoport BL; Chasen MR; Abratt RP; Cronje N; Fourie L; McMichael G; Hacking D
    Ann Oncol; 2002 Mar; 13(3):412-5. PubMed ID: 11996472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
    Kasseyet S; Astoul P; Boutin C
    Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
    Bakhshandeh A; Bruns I; Traynor A; Robins HI; Eberhardt K; Demedts A; Kaukel E; Koschel G; Gatzemeier U; Kohlmann T; Dalhoff K; Ehlers EM; Gruber Y; Zumschlinge R; Hegewisch-Becker S; Peters SO; Wiedemann GJ
    Lung Cancer; 2003 Mar; 39(3):339-45. PubMed ID: 12609573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
    Steele JP; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
    J Clin Oncol; 2000 Dec; 18(23):3912-7. PubMed ID: 11099320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer EA; Evans WK; Murray N; Kocha W; Wierzbicki R; Wilson K
    Invest New Drugs; 1988 Dec; 6(4):327-9. PubMed ID: 3229945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
    Gunduz S; Mutlu H; Goksu SS; Arslan D; Tatli AM; Uysal M; Coskun HS; Bozcuk H; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(20):8843-6. PubMed ID: 25374217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
    Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
    J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
    Krug LM; Heelan RT; Kris MG; Venkatraman E; Sirotnak FM
    J Thorac Oncol; 2007 Apr; 2(4):317-20. PubMed ID: 17409804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
    J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
    Belani CP; Adak S; Aisner S; Stella PJ; Levitan N; Johnson DH;
    Clin Lung Cancer; 2004 Jul; 6(1):43-7. PubMed ID: 15310416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral etoposide in the treatment of malignant mesothelioma. A phase II study.
    Tammilehto L; Maasilta P; Mäntylä M; Salo J; Mattson K
    Ann Oncol; 1994 Dec; 5(10):949-50. PubMed ID: 7696167
    [No Abstract]   [Full Text] [Related]  

  • 20. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.